Interferon (IFN)-alpha is an innate immune cytokine that induces significant depressive symptoms in clinical populations. A number of mechanisms have been considered regarding the relationship between IFN-alpha and depression, including the effects of IFN-alpha on the hypothalamic-pituitary-adrenal (HPA) axis. Here, we examined the impact of mouse interferon (mIFN)-alpha and its signaling pathways on the functioning of the glucocorticoid receptor (GR), which plays a key role in HPA axis regulation. mIFN-alpha treatment (100-1000 IU/ml) of HT22 mouse hippocampal cells for 24 h was found to significantly inhibit dexamethasone (DEX)-induced GR-mediated MMTV-luciferase activity and significantly decrease DEX-induced GR-binding to its DNA response element. Of note, mIFN-alpha treatment for 24 h had no effect on DEX-induced GR translocation or GR protein expression. Inhibition of DEX-induced GR function by mIFN-alpha was significantly reversed by pharmacological inhibition of janus kinase/signal transducer and activator of transcription (Jak-STAT) signaling pathways, but not by inhibition of p38 mitogen-activated protein kinase. Moreover, pretreatment of cells with siRNA targeted to STAT5, but not STAT1 or STAT2, significantly attenuated IFN-alpha inhibition of DEX-induced MMTV-luciferase activity. Immunoprecipitation experiments revealed nuclear co-immunoprecipitation of activated STAT5 and GR following IFN-alpha plus DEX treatment. Taken together, these results indicate that negative regulation of GR function by IFN-alpha in hippocampal HT22 cells is mediated by activation of Jak/STAT signaling pathways leading to nuclear STAT5-GR protein-protein interactions. Given the role of GR in depressive disorders, IFN-alpha effects on GR function in cells of hippocampal origin may contribute to HPA axis alterations and depressive symptoms in IFN-alpha-treated patients.
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Introduction
Interferon (IFN)-alpha is a cytokine of the innate immune response that has both antiviral and antiproliferative activities (Abbas and Lichtman, 2003) . Accordingly, IFN-alpha has become a mainstay in the treatment of certain cancers such as malignant melanoma and viral infections including hepatitis C (Heathcote, 2007) . Despite its therapeutic efficacy, IFN-alpha is well-known to induce the development of depressive symptoms in 20-50% of patients, depending on the dose (Raison et al., 2005) .
A number of mechanisms have been considered regarding the relationship between IFN-alpha and depression including the effects of IFN-alpha on the hypothalamic-pituitary-adrenal (HPA) axis. For example, one study found that patients who developed major depression during IFN-alpha therapy were more likely to exhibit exaggerated HPA axis responses to the first IFN-alpha injection (Capuron et al., 2003) . Given the role of corticotropin releasing hormone (CRH) in the regulation of HPA axis outflow, these results suggest that increased sensitivity of CRH pathways to IFN-alpha may represent a vulnerability factor for the development of IFN-alpha-induced depression. Of note, hypersecretion of CRH is believed to play a central role in the development of depression, and IFN-alpha has been shown to stimulate CRH expression in the hypothalamus as well as the amygdala of laboratory animals (Raber et al., 1997) . IFN-alpha has also been shown to lead to flattening of the diurnal cortisol slope and increased evening cortisol concentrations, both of which were correlated with increased IFN-alpha-induced depressive symptoms (Raison et al., 2008) .
CRH hypersecretion in major depression and flattening of the cortisol slope is believed to be related in part to impaired negative feedback regulation of the HPA axis by glucocorticoids, an effect that may be mediated by decreased glucocorticoid receptor (GR) function (Nemeroff, 1996; Raison and Miller, 2003) . Indeed, depressed patients have been shown to exhibit decreased GR function both in vivo and in vitro as manifested by failure of the synthetic glucocorticoid dexamethasone (DEX) to suppress cortisol secretion during the DEX suppression test (DST) and DEX-CRH test (Holsboer, 2000; Ising et al., 2005) and reduced sensitivity of peripheral blood mononuclear cells to the in vitro inhibitory effects of DEX on mitogen-in-
